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I N T R O D U C T I O N
Infections of cardiac implantable electronic devices (CIEDs) are an emerging 
problem because of increasing implant rates and comorbidities. If undiagnosed and 
untreated, CIED infection is associated with high mortality. Following the new guide-
lines concerning the use of cardiac resynchronization therapy devices in patients with 
congestive heart failure,1 CIED implantation has grown further. Unfortunately, this 
trend has been accompanied by an increase in infection rate, probably due to an in-
crease in comorbidities. A recent analysis of US data2 showed that infection rate grew 
from 1.61% in 1993 to 2.41% in 2008, possibly due to two factors: ageing of popula-
tion and increased use of more complex devices. Several studies3,4 have found that the 
most important risk factors for infection are re-intervention, with device replacement 
increasing with ageing of the population, and use of dual and triple chamber devices 
having increased over the last several years.
Early diagnosis and correct treatment of this situation is of great importance; if the 
local infection is not correctly treated and bacteremia or device endocarditis is present, 
in-hospital mortality can rise from 5% to 29%.5 The presentation, consequences, and 
treatment of device infections vary according to the location and extent of infection 
and the clinical characteristics of the patient.6,7
Cardiac device infections (CDI) may be classified by the mode of infection as 
primary infections, in which the device and/or pocket itself is the source of infection, 
usually due to contamination at the time of implant, and secondary infection, in which 
the leads (and then sometimes the device and the pocket) are seeded due to bacteremia 
from a different source.
R I S K  F A C T O R S
A variety of factors and comorbid conditions have been associated with pacemaker 
and ICD infection.8-11
 - Recent manipulation of the device, particularly elective secondary manipulations 
such as pulse generator replacement
 - Temporary pacing prior to permanent device placement
 - Diabetes mellitus
 - Underlying malignancy
 - Operator inexperience
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AbbreviAtions
CDI = cardiac device infections
CIEDs = cardiac implantable electronic 
devices
CoNS = coagulase-negative 
Staphylococcus
ICD = implantable cardioverter 
defibrillator
MIC = minimal inhibitory concentration
MRSA = methicillin resistant 
Staphylococcus aureus
PPM = permanent pacemaker
VRE = vancomycin resistant enterococcus
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 - Advanced patient age
 - Prior treatment with anticoagulants or glucocorticoids
 - Pocket revision
 - Heart failure
 - Renal dysfunction (glomerular filtration rate <60 mL/min)
 - Female gender
Device infections are generally considered in two cat-
egories:
 - Pocket infections: the infection involves the subcutaneous 
pocket containing the device and the subcutaneous seg-
ment of the leads (i.e., not the transvenous segment). In 
some cases, part of the device or lead erodes through the 
overlying skin. Such an erosion can occur without overt 
evidence of infection, but there is inescapable contami-
nation of the site and these cases are managed as pocket 
infections.
 - Deeper infection: the infection involves the endovascular 
portion of the lead, usually with associated bacteremia and/
or endovascular infection. Deep infection can occur with 
or without involvement of the generator pocket and can 
include device-related endocarditis in which there may be 
vegetations on the intracardiac portion of the lead.
The diagnosis of CIED infection is more obvious in 
patients with inflammatory findings at the generator pocket 
consistent with infection. In contrast, a diagnosis of CIED 
infection is difficult when there is blood stream infection, but 
no other discernible clinical or echocardiographic evidence 
of CIED involvement. Patients with suspected device-related 
endocarditis should have at least three sets of blood cultures 
obtained before antibiotics are initiated.12 Staphylococcal 
species cause the bulk of CIED infections,14-20 and account 
for 60% to 80% of cases in most reported series. A variety 
of coagulase-negative Staphylococcus (CoNS) species have 
been described to cause CIED infections.21 CoNS is well 
recognized as a common cause of microbiological specimen 
contamination, and thus, repeated isolation of the same species 
of CoNS with an identical antibiotic susceptibility pattern is 
desired to support its role as an etiologic agent in CIED infec-
tions. Polymicrobial infection sometimes involves more than 
1 species of CoNS.16,20,21 The prevalence of oxacillin resistance 
among staphylococcal strains has varied among studies, but 
it is prevalent and should influence initial empirical therapy 
decisions in CIED infections. Corynebacterium species, Pro-
pionibacterium acnes, Gram-negative bacilli16,17 including 
Pseudomonas aeruginosa,23 and Candida species account for 
a minority of CIED infections. Fungi other than Candida24 
and nontuberculosis mycobacteria25 are rarely identified as 
pathogens in CIED infection.
C I E D  I N F E C T I O N  S T U D y
P U R P O S E
The purpose of this study was to assess recent data in a 
tertiary hospital for management of CIED infection according 
to the proper antibiotic therapy on the basis of the responsible 
micriobiological factors and antibiotic susceptibility testing.
M E T h O D S
Over the last two years, clinical samples from patients with 
suspected CDI were examined with Gram stain, cultured in 
common and selective media and broths, in aerobic, micro-
aerophilic and anaerobic conditions. The identification of 
the isolated microorganisms and the antibiotic susceptibility 
testing was performed with the automated system VITEK 2 
and MIC E test strips (AB Biodisk).
R E S U l T S
47 patients out of 82 (57.3%) suspected with CIED in-
fection were confirmed microbiologically based on positive 
cultures from cardiac device specimens. A total of 28 out of 
47 (59.6%) patients had pus discharged from the infected area 
and 19 (40.4%) had cardiac device infections, involving the 
pulse generator in 6 (2 defibrillators, 4 PPM), pocket (n=5) 
or other (n=2) tissue in 7, and electrode leads in 6. Polymi-
crobial infection was confirmed in 3/47 (6.3%) patients. A 
total of 35/82 (42.7%) suspected samples were negative (30 
trauma infections, 3PPM, 2 pocket infections). Results are 
shown in Table 1.
No relapse or recurrence of the device infection was 
found with the same organism based on similar antibiogram. 
TAblE 1. CIED Infections
suspected CDI 82
CIED infection 47 (57.3%)
pus discharged from the infected area 28 (59.6%)




device pocket tissue 5
other tissue 2
electrode leads 6
polymicrobial infection 3 (6.3%)
CDI = cardiac device infection; CIED = cardiac implantable electronic 




C O N C l U S I O N S
CIED infection was confirmed microbiologically in 57.3% 
suspected CIED patients. The predominant causative CDI 
pathogens included common skin flora microorganisms, such 
as coagulase negative staphylococci (CoNS), S. aureus, and 
Streptococcus spp. The most frequent etiological agents were 
CoNS (14%) followed by gram-negative bacilli including Kleb-
siella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, 
Acinetobacter baumanii, Citrobacter koseri, Serratia marcescens, 
Escherichia coli, and Providencia stuartii. No anaerobes or 
mycobacteria were detected as etiological agents.
The microorganisms that cause CIED infections may 
be acquired either endogenously from the skin of patients 
or exogenously from the hospital environment or from the 
hands of hospital workers. The Enterococcus strains were 
vacomycin resistant (VRE); 1 out of 4 strains of S. aureus 
was methicillin-resistant Staphylococcus aureus (MRSA) 
and with MIC vancomycin >1. The detection of these strains 
with low sensitivity to vancomycin is very important because if 
one uses vancomycin with MIC ≥1μg/ml, one may encounter 
therapeutic failure. That is why one could use a beta-lactam 
antibiotic (preferably daptomycin) (Grade 1B).
The presence of methicillin-resistant S. aureus (although 
in low concentrations) and the presence of multidrug resistant 
Gram negative baciili, such as A. baumannii, K. pneumoniae 
and Serratia marcescens which are present in the nosocomial 
environment suggest that a healthcare environment is the 
site of infection acquisition. As Staphylococci are the most 
common pathogens for CIED infections, empiric antibiotics 
for suspected CDI should include coverage for staphylococci, 
while awaiting microbiology culture results. These findings 
should assist clinicians in identifying CIED patients who are at 
increased risk of infection, as well as in developing strategies 
to minimize the modifiable risks.
All patients in the present study received antimicrobial 
treatment. Most patients (97%) received a combination of 
intravenous and oral antibiotics. Only 3% were treated with 
oral antibiotics alone. It is very important that patients with 
inescapable contamination of the site, when part of the device 
or lead erodes through the overlying skin without proven 
evidence of infection, must be treated as pocket infections. 
The development of resistance of some strains along with the 
incidence of these infections have to be dealt with continuous 
surveillance and wisely used therapy. Improvement of surveil-
lance is crucial in recognizing emergence of highly resistant 
strains. Early recognition and prompt empirical treatment are 
essential to improve outcomes.
TAblE 2. Microbiology of CIED Infections
Gram positive cocci 25 Gram
negative bacilli 22
Fungi: Candida albicans 2  
Total microorganisms 49
Staphylococcus aureus oxacillin negative 3
Staphylococcus aureus oxacillin positive 1
Staphylococcus epidermidis 10
Other coagulase negative Staphylococci 3
Staphylococcus lugdunensis 1
Streptococcus viridans 1













FIGURE 1. Microbiology of PPM/ICD infections (n=49).
Thirty patients had CDI after initial device implantation and 
3 patients after a revision (i.e., system upgrade, lead revision, 
or generator replacement).
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